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Abstract. 
 
Platelet/endothelial cell adhesion molecule 
(PECAM-1) is a cell adhesion molecule of the immuno-
globulin superfamily that plays a role in a number of 
vascular processes including leukocyte transmigration 
through endothelium. The presence of a specific 19–
amino acid exon within the cytoplasmic domain of 
PECAM-1 regulates the binding specificity of the mole-
cule; specifically, isoforms containing exon 14 mediate 
heterophilic cell–cell aggregation while those variants 
missing exon 14 mediate homophilic cell–cell aggrega-
tion. To more precisely identify the region of exon 14 
responsible for ligand specificity, a series of deletion 
mutants were created in which smaller regions of exon 
14 were removed. After transfection into L cells, they 
were tested for their ability to mediate aggregation. For 
heterophilic aggregation to occur, a conserved 5–amino 
acid region (VYSEI in the murine sequence or VYSEV 
in the human sequence) in the mid-portion of the exon 
was required. A final construct, in which this tyrosine 
was mutated into a phenylalanine, aggregated in a ho-
mophilic manner when transfected into L cells. Inhibi-
tion of phosphatase activity by exposure of cells ex-
pressing wild type or mutant forms of PECAM-1 to 
sodium orthovanadate resulted in high levels of cyto-
plasmic tyrosine phosphorylation and led to a switch 
from heterophilic to homophilic aggregation. Our data 
thus indicate either loss of this tyrosine from exon 14 or 
its phosphorylation results in a change in ligand speci-
ficity from heterophilic to homophilic binding. Vascular 
cells could thus determine whether PECAM-1 func-
tions as a heterophilic or homophilic adhesion molecule 
by processes such as alternative splicing or by regula-
tion of the balance between tyrosine phosphorylation 
or dephosphorylation. Defining the conditions under 
which these changes occur will be important in under-
standing the biology of PECAM-1 in transmigration, 
angiogenesis, development, and other processes in 
which this molecule plays a role.
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1. 
 
Abbreviations used in this paper
 
: huPECAM-1, human platelet/endo-
thelial cell adhesion molecule; muPECAM-1, murine platelet/endothelial
cell adhesion molecule; PBP, PECAM binding protein; PECAM-1, plate-
let/endothelial cell adhesion molecule.
 
P
 
latelet
 
/endothelial cell adhesion molecule (PE-
 
CAM-1, CD31)
 
1
 
 is a 130-kD integral membrane
glycoprotein of the immunoglobulin superfamily
 
expressed on endothelial cells, platelets and leukocytes
(Newman et al., 1990; reviewed in DeLisser et al., 1994
 
a
 
 and
Newman, 1997). Although the full range of physiologic func-
tions of PECAM-1 are not yet known, evidence exists to
support a role for this molecule in leukocyte transmigration
through endothelium (Muller et al., 1993; Vaporciyan et
al., 1993; Bogen et al., 1994), release of leukocytes from
bone marrow (Leavesley et al., 1994), cardiovascular de-
velopment (Baldwin et al., 1994; Pinter et al., 1997), and
angiogenesis (DeLisser et al., 1997; Matsumura et al., 1997).
PECAM-1 has been noted to function as both an adhe-
sion molecule (Albelda et al., 1991; Muller et al., 1992; De-
Lisser et al., 1993) and a signal transduction molecule
(Tanaka et al., 1992; Piali et al., 1993; Berman and Muller,
1995). It is somewhat unique as a cell adhesion molecule,
however, in that conditions have been defined (see below)
in which PECAM-1 mediates homophilic interactions
(DeLisser et al., 1994
 
b
 
; Yan et al., 1995) or heterophilic in-
teractions to ligands such as heparin-containing proteogly-
cans (DeLisser et al., 1993; Watt et al., 1993), the integrin
 
a
 
v
 
b
 
3 (Piali et al., 1995; Buckley et al., 1996), and an uni-
dentified ligand on activated T cells (Prager et al., 1996).
Although we believe that increased cell surface density,
through its ability to favor homodimer formation, may be
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a factor in regulating PECAM-1 function (Sun et al., 1996),
the molecular mechanisms that define this ligand specific-
ity are still unknown.
Recent analysis of PECAM-1 expression in the develop-
ing mouse embryo has revealed the presence of multiple
isoforms of murine PECAM-1 (muPECAM-1) that ap-
pear to result from the alternative splicing of exons encod-
ing cytoplasmic domain sequences (exons 10–16) (Baldwin
et al., 1994). Forms of human PECAM-1 (huPECAM-1)
(Goldberger et al., 1994) and bovine PECAM-1 (Osawa et
al., 1997) with alternatively spliced cytoplasmic domains
have also been identified. To investigate the functional
consequences of alternatively spliced muPECAM-1 cyto-
plasmic domains, L cells were transfected with cDNA for
each variant and their ability to promote cell aggregation
was compared (Yan et al., 1995). In this assay, full-length
muPECAM-1 and all three isoforms containing exon 14
behaved like full-length huPECAM-1 in that they medi-
ated heterophilic aggregation. In contrast, all muPECAM-1
variants missing exon 14 exhibited homophilic aggrega-
tion. Exon 14 thus appeared to be an important modulator
of the ligand and adhesive interactions of the extracellular
domain of muPECAM-1. These observations were con-
firmed and expanded in a recent study examining the role
of exon 14 in the function of huPECAM-1. Similar to the
results with muPECAM-1, all L cell lines expressing mu-
tants of huPECAM-1 lacking exon 14 exhibited homophilic
aggregation while all those expressing huPECAM-1 pos-
sessing exon 14 aggregated in a heterophilic fashion (Sun
et al., 1996).
These data indicate that exon 14 of the cytoplasmic do-
main contains specific information that regulates the ligand
choice of PECAM-1 in transfected L cells. Although alter-
ations in the cytoplasmic domain have clearly been shown
to affect ligand binding of many cell adhesion molecules
(CAMs) with regard to affinity, to our knowledge, alterna-
tive splicing of a cytoplasmic domain has not been re-
ported to regulate ligand specificity of a CAM.
A key question raised by our findings is how changes in
one exon of the cytoplasmic domain of PECAM-1 can dra-
matically affect the binding characteristics of the molecule.
Exon 14 is a small exon that encodes 19 amino acids (Kirsch-
baum et al., 1994). A large portion of the amino acids in
this exon are highly conserved in mice (ALGTRATE-
TVYSEIRKVDP) and humans (DLGKKDTETVYSE-
VRKAVP) (Baldwin et al., 1994). Within this exon, there
are five amino acids that could potentially serve as phos-
phorylation sites, including one tyrosine in the context of a
possible SH2 binding domain (YSEI or YSEV). The car-
boxyl end of the exon has a proline, as well as a number of
highly charged amino acids. It is currently unknown which
sequences in this exon are regulatory. The purposes of this
investigation were to more precisely identify the region of
exon 14 responsible for ligand specificity and to use this in-
formation to try to begin to understand the mechanism by
which this part of the molecule might regulate function.
Our experiments suggest that the key residue of exon 14 is
the tyrosine at amino acid 686 and that either loss of this
tyrosine from exon 14 or its phosphorylation results in a
change in ligand specificity from heterophilic binding to
homophilic binding. These results imply that vascular cells
could thus determine whether PECAM-1 functions as a
 
heterophilic or homophilic adhesion molecule by pro-
cesses such as alternative splicing or by regulation of the
balance between tyrosine phosphorylation or dephosphor-
ylation.
 
Materials and Methods
 
Construction of PECAM-1 Cytoplasmic
Domain Mutants
 
A series of mutant muPECAM-1 constructs were produced in which por-
tions of exon 14 were removed or mutated (see Fig. 1). The altered forms
of PECAM-1 were constructed from the full-length wild-type murine
form of PECAM-1 cDNA subcloned into the PcDNA/Neo vector (Yan et
al., 1995). This full-length cDNA served as the template for the sequence
overlap extension (SOE) polymerase chain reactions (Horton et al., 1990).
The following two outside primers were used as the external primers
for these reactions: a sense primer (primer A) (5
 
9
 
-
 
1395
 
TATGAAAGCA-
AAGAGTGA
 
1412
 
-3
 
9
 
) flanking the BstEII restriction site within the 6th
extracellular Ig-like domain, and an antisense primer (primer B) (5
 
9
 
-
 
2253
 
CGAATGCATCCAGGAATCGGCTGCTCT
 
2235
 
-3
 
9
 
) complimentary to
a region 70-bp downstream from the stop codon of muPECAM-1 and car-
rying an NsiI recognition sequence to facilitate subcloning. For each of the
mutants described below a set of inside primers was constructed, each
spanning the area of deletion or mutation and each having substantial
overlap. The sense inside primer was used in a PCR reaction with primer
B to create a fragment that would become the 3
 
9
 
 end of the cytoplasmic do-
main. The antisense inside primer was used in a PCR reaction with primer
A to create a fragment that would become the 5
 
9
 
 end of the cytoplasmic
domain. Each of these two fragments were then reacted together in a PCR
reaction to create a longer fragment. These SOE products were then di-
gested with BstEII and NsiI and ligated into PcDNA/neo vector contain-
ing muPECAM-1 previously cut with the same restriction enzymes.
The following pairs of primers were used as inside primers in the initial
PCR to create the following mutants:
 
PECAM-1-
 
D
 
5
 
9
 
 exon 14 (Missing ALGTRATET in Exon 14). 
 
Sense primer
(5
 
9
 
-
 
2134
 
 
 
EXON14
 
ACAGAGACG
 
2142EXON15
 
ATTCTCATGGAAAA-3
 
9
 
); Anti-
sense primer (5
 
9
 
-
 
EXON15
 
CATGAGATT
 
2142
 
 
 
EXON14
 
CGTCTCTGTGGC-
TC
 
2129
 
-3
 
9
 
).
 
PECAM-1-
 
D
 
3
 
9
 
 exon14 (Missing VYSEIRKVDP in Exon 14). 
 
Sense
primer (5
 
9
 
-
 
EXON13
 
CCTCACCAA
 
EXON14
 
GTGTACAGTGAGAT-3
 
9
 
); An-
tisense primer (5
 
9
 
-
 
EXON14
 
ACTGTACAC
 
EXON13
 
TTGGTGAGGCTC-3
 
9
 
).
 
PECAM-1-
 
D
 
RKVDP (in Exon 14). 
 
Sense primer (5
 
9
 
-
 
2148
 
 
 
EXON14
 
CAGT-
GAGATC
 
EXON15
 
AATCTCATGGAAAAC
 
2187
 
-3
 
9
 
); Antisense primer (5
 
9
 
2182
EXON15
 
CCATGAGATT
 
EXON
 
 
 
14
 
GATCTC ACTGTA CAC
 
2145
 
-3
 
9
 
).
 
PECAM-1-686Y
 
®
 
F (in Exon 14). 
 
Sense primer (5
 
9
 
-
 
2279
 
GAGACGGTG-
TTCAGTGACATCCGGAAG
 
2305
 
-3
 
9
 
); Antisense primer (5
 
9
 
-GATCTC-
ACTGAACACCGTCTCTGTGGC-3
 
9
 
).
The resulting ligation products were transformed into competent
MC1061.p3 cells. Initially, antibiotic resistant colonies were screened by
digestion of miniprep plasmid DNA using the enzyme HincII or BsmaI.
These enzymes would lose a restriction site if a portion of exon 14 was de-
leted. Other mutants, in which we could not take advantage of this tactic,
were simply checked for insert size by digestion with BstEII and NsiI. All
positive clones were then confirmed by sequence analysis using an anti-
sense Sp6 primer 3
 
9
 
 of the mutation site. Candidate clones finally were
tested for efficient protein translation by transfection into Cos-1 cells be-
fore going on to permanent transfections of L cell fibroblasts.
 
Tissue Culture and Transfection of L Cells
 
Murine L cells were cultured in RPMI medium with 10% FBS plus
glutamine, and antibiotics. The procedure to transfect PECAM-1 cDNA
into these cells has been previously described in detail (DeLisser et al.,
1994
 
b
 
). Briefly 10
 
5
 
 L cells were plated on a 100-mm tissue culture plate
the night before transfection. The day of the transfection the cells were
washed with PBS and fed DME with 10% FBS. Using the CaPO
 
4
 
 method
of transfection, 10 
 
m
 
g of muPECAM-1 cDNA and 14 
 
m
 
g of calf thymus
DNA were combined with BBS and CaCl
 
2
 
 to form a DNA precipitate.
This precipitate was added to the cells in culture and allowed to incubate
 
z
 
20 h. After 20 hours the cells were washed three times with PBS and fed
RPMI medium with 10% FBS. 24 h after transfection, the cells were split
1:10, and 48 h after transfection the cells were fed G418 selection medium 
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(0.5 mg/ml). The G418-resistant colonies were grown up and tested by
FACS
 
®
 
 for surface expression of PECAM-1.
To isolate cells with higher expression levels of PECAM-1, cells were
sorted using magnetic beads coupled with anti–PECAM-1 antibody. The
night before sorting, the transfected L cells were trypsinized and replated
in the original tissue culture dishes. On the day of sorting, the transfected
L cells were washed with PBS twice and dissociated with enzyme-free cell
dissociation solution (Specialty Media, Inc., Lavallette, NJ). The cell pel-
let was resuspended and incubated in 400 
 
m
 
l of rat anti–mouse PECAM-1
primary antibody (mAb 390) for 1 h on a nutator at 4
 
8
 
C. 1 h later, the cells
were spun down, washed with PBS twice, resuspended, and then incu-
bated in 400 
 
m
 
l of RPMI medium with 1% FBS that contained 10 
 
m
 
l of
Dynabeads M-450 coated with sheep anti–rat IgG (Dynal, Inc. Great
Neck, NY) for 30 min on a nutator at 4
 
8
 
C. After 30 min, the bead-coated
cells were resuspended in 3 ml of PBS, transferred into a snap cap tube,
and concentrated using a Dynal Magnetic Particle Concentrator (Dynal,
Inc.). The sorted cells were washed with PBS three times and cultured in
RPMI medium with 10% FBS plus G418.
In addition to the muPECAM-1 L cell lines, experiments were also
conducted with L cells transfected with full length huPECAM-1 and with
a truncated form of huPECAM containing the extracellular and trans-
membrane domains along with exon 9, 10, and 14, PECAM-1(
 
1
 
)9,10,14
(Sun et al., 1996).
 
Antibodies
 
The following antibodies were used: (
 
a
 
) anti–muPECAM-1 mAb 390 gen-
erated in rat after immunization with mouse 32D leukocyte cell line
screened against muPECAM-1
 
D
 
12,15 (Baldwin et al., 1994); (
 
b
 
) anti–
huPECAM-1 polyclonal antibody “Houston” (Albelda et al., 1991); and
(
 
c
 
) anti–huPECAM-1 mAb 1.3 generously provided by P. Newman
(Blood Center of Southeastern Wisconsin, Milwaukee, WI).
 
FACS
 
®
 
 Analysis. 
 
L cells transfected with muPECAM-1 isoforms were
nonenzymatically removed from a T-25 tissue culture flask, washed with
PBS, and treated with mAb 390 for 1 h at 4
 
8
 
C. The primary antibody was
then removed and the cells were washed with PBS. A dilution of 1:200 of
fluorescein isothiocyanate–labeled goat anti–rat secondary antibody was
added to the cells for 30 min at 4
 
8
 
C. The cells were then washed again in
PBS and flow cytometry was performed using an Ortho Cytofluorograph
50H cell sorter equipped with a 2150 data handling system (Ortho Instru-
ments, Westwood, MA). All cell lines established had an approximate
mean fluorescence of 110–125 (a level comparable to that seen on endo-
thelial cells) and were 
 
.
 
90% positive for muPECAM-1.
 
Sodium Orthovanadate Treatment
 
A working solution at 92 mg/ml of sodium orthovanadate (Sigma Chemical
Co., St. Louis, MO) was boiled and cooled. The appropriate amount was
added to RPMI/10% FBS to a final concentration of 0.5 mM. The L cells
were then incubated for the indicated times in this vanadate-containing me-
dia. The time of incubation ranged from overnight exposure to 1-h exposure.
 
Immunoprecipitation and Immunoblotting
 
Nonionic detergent cellular extracts were prepared by adding small vol-
umes of TNC (0.01 M Tris acetate, pH 8.0, 0.5% NP-40, 0.5 mM Ca
 
2
 
1
 
)
with 2 mM PMSF and 100 mM vanadate to cells that had been trypsinized
and washed. Cells were lysed on ice for 20 min. The resulting extracts
were preabsorbed for 1 h at 4
 
8
 
C with protein G–conjugated Sepharose
beads (Pharmacia Fine Chemicals, Piscataway, NJ). After removal from
the beads, the precleared supernatants were transferred to another eppen-
dorf with fresh protein G–Sepharose beads and 2 
 
m
 
l of Houston poly-
clonal antiserum was added for each 100 
 
m
 
l of lysate. Immunoprecipita-
tion was carried out at 4
 
8
 
C for 2 h. After the immunoprecipitation, the
beads were washed five times with DOC wash (50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1% Triton X-100, 5% deoxycholate, and 0.1% SDS). The
sample was then dissolved in loading buffer (62.5 mM Tris base, 2% SDS,
10% glycerol, pH 6.8), and electrophoresed on a 6% polyacrylamide gel.
After resolving on the SDS-PAGE gel, the proteins were transferred to
nitrocellulose membranes. The membranes were blocked for at least 1 h
in 4% BSA/PBS/.02% azide. Blots were then incubated in either 1 
 
m
 
g/ml
mouse anti-phosphotyrosine mAb (clone 4G10; Upstate Biotechnology
Inc., Lake Placid, NY) or in the polyclonal anti–huPECAM-1 antiserum
at a dilution of 1:700 for 1 h at room temperature. After extensive washing
for 1 h, the blots were incubated in HRP donkey anti–mouse Ig (Jackson
Immunoresearch Laboratories, Inc., West Grove, PA) at room tempera-
 
ture for 1 h. After washing, the blots were developed with the chemilumi-
nescence reagent (New England Nuclear, Boston, MA) according to the
manufacturer’s instructions.
 
Aggregation of L Cell Transfectants
 
The aggregation assays used in these studies have been described previ-
ously in detail by DeLisser et al. (1993). Briefly, stable L cell transfectants
that had been plated (0.8–1 
 
3
 
 10
 
6
 
 cells/75-cm
 
2
 
 flask) and grown overnight
were nonezymatically removed. The cells were washed twice in 10 mM
EDTA in PBS, pH 7.2, and twice in HBSS without divalent cations. After
washing, the cells were resuspended at a final concentration of 0.8–1 
 
3
 
 10
 
6
 
cells/ml in HBSS with or without 1 mM calcium. Where indicated, the
polyclonal anti–huPECAM-1 antibody Houston was added at a final con-
centration of 100 
 
m
 
g/ml. After the cells had been dispersed into a single
cell suspension, 1-ml aliquots were transferred to wells in a 24-well nontis-
sue culture plastic tray (Costar Corp., Cambridge, MA) that had been pre-
viously blocked with 2% BSA in HBSS for 1 h and washed thoroughly
with HBSS immediately before use. The nontissue culture-treated trays
containing the suspended L cells were rotated on a gyratory platform at
100 rpm, for 45 min at 37
 
8
 
C. Aggregation was quantified by examining
representative aliquots from each sample on a hemocytometer grid using
phase contrast optics. The number of single cells (cells in aggregates of 3
or less) versus those present in aggregates of greater than three cells were
counted from four 1-mm squares. At least 400 cells were counted from
each sample. Data were expressed as the percent total cells present in ag-
gregates.
 
Mixed Aggregation Assay
 
To determine if the muPECAM-1–dependent L cell aggregation was me-
diated by homophilic or heterophilic mechanisms, mixed aggregation as-
says were performed as described in detail (DeLisser et al., 1993). In these
experiments, L cell aggregation was performed by mixing nontransfected
and transfected L cells, with the nontransfected L cells fluorescently la-
beled before mixing. After the nontransfected cells had been washed once
with EDTA, they were resuspended in HBSS to a total volume of 1 ml. 1
ml of rhodamine-conjugated dye solution at a final concentration of 1 mM
(Sigma Chemical Co.), in a buffer provided by the manufacturer, was
added, followed by incubation at room temperature for 5–10 min. Label-
ing was terminated by adding an equal volume of FBS and washing the
cells in HBSS. The second EDTA wash and the two HBSS washes were
then performed as described above. Each set of cells, one labeled, the
other unlabeled, were resuspended at 0.8–1 
 
3
 
 10
 
6
 
 cells/ml. 500-
 
m
 
l aliquots
of each were combined in the wells of the 24-well nontissue culture plate
and allowed to aggregate as described above. After the aggregation was
complete, the cells were viewed under epifluorescence. The number of
fluorescent cells in each aggregate of a given size was counted. Quantita-
tive analysis of the aggregating cell populations was performed as de-
scribed by Sieber and Roseman (1981).
 
Results
 
The Region of Exon 14 That Regulates Heterophilic 
Aggregation Is within 5 Amino Acids in the 3
 
9
 
 Portion 
of Exon 14
 
Since the full-length form of muPECAM-1 (Fig. 1 
 
A
 
) me-
diates heterophilic aggregation and a form missing exon 14
mediates homophilic aggregation (Fig. 1 
 
B
 
), we initially
designed two additional muPECAM-1 constructs in which
either the 9 amino acids from the NH
 
2
 
-terminal portion of
exon 14 (muPECAM-
 
D
 
5
 
9
 
 exon 14; Fig. 1 
 
C
 
) or the 10
amino acids from the carboxyl-terminal portion of exon 14
(muPECAM-
 
D
 
3
 
9
 
 exon 14; Fig. 1 
 
D
 
) were removed. These
constructs were sequenced and transfected into L cells.
After selection in G418, cells expressing the constructs
were enriched using magnetic beads and at least three sep-
arate cell lines with equivalent muPECAM-1 expression
selected.
Fig. 2 demonstrates the cell composition of aggregates 
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when these cell lines were subjected to mixed aggregation
studies. The construct lacking the NH
 
2
 
-terminal portion of
exon 14, muPECAM-
 
D
 
5
 
9
 
 exon 14, showed a bell-shaped
distribution pattern indicating heterophilic aggregation
(Fig. 2 
 
A
 
) similar to that seen with full-length muPECAM-1
(Yan et al., 1995). In contrast, the construct lacking the
carboxyl-terminal portion of exon 14, muPECAM-
 
D
 
3
 
9
 
 exon
14, showed a pattern consistent with homophilic aggrega-
tion (Fig. 2 
 
B
 
) similar to that seen with the muPECAM-1
mutant lacking exon 14 (Yan et al., 1995). These studies
indicate that the region of exon 14 that regulates het-
erophilic aggregation is within the last 10 amino acids
(VYSEIRKVDP) of the carboxyl portion of exon 14.
This carboxyl end of exon 14 appeared to have two po-
tential functional regions. The first was a 5–amino acid re-
gion (VYSEI) that places tyrosine in the context of a po-
tential SH2 binding site (Songyang et al., 1993). The
second region (RKVDP) was a highly charged region with
a terminal proline. To localize the regulatory region more
precisely, an additional construct was made in which only
the last 5 amino acids in the carboxyl end of exon 14 were
removed (muPECAM-
 
D
 
RKVDP, Fig. 1 E). After trans-
fecting and isolating L cells expressing this construct at
comparable levels, multiple clones were tested in mixed
aggregation assays. As shown in Fig. 2 C, these cells aggre-
gated in a heterophilic manner.
Figure 1. Cytoplasmic domain mutants of muPECAM-1. The
PECAM-1 cytoplasmic domain is encoded by exons 9–16. A se-
ries of muPECAM-1 mutants in which specific exons encoding
regions of the cytoplasmic domain had been deleted were con-
structed and expressed in L cells as described in Materials and
Methods. The extracellular domain and transmembrane regions
were wild type and the same for each construct. The figure indi-
cates: the name of each construct; the regions of exon 14 that
were deleted or mutated (note: muPECAM-D59 exon 14 is de-
leted in the sequence ALGRTRATET; muPECAM-D39 exon 14
is deleted in the sequence VYSEIRKVDP); and the aggregation
behavior of murine L cells stably expressing each construct.
Figure 2. Effect of deletion of exon 14 or
mutation of tyrosine in exon 14 on muPE-
CAM-1–dependent aggregation. Mixed
aggregation studies were performed with
L cell transfectants expressing muPE-
CAM-1–D59 exon 14 (A), muPECAM-
1-D39 exon 14 (B), muPECAM–1-DRKVDP
(C) or muPECAM-1–686Y®F (D) in
which equal numbers of nontransfected
and transfected L cells were mixed to-
gether after fluorescent labeling of one of
the cell lines. After incubation, the num-
ber of labeled cells within each six-cell ag-
gregate was counted. muPECAM-1-D59
exon 14 (A) and muPECAM-1-DRKVDP
(C) formed aggregates composed prima-
rily of mixtures of nontransfected and trans-
fected cells consistent with a heterophilic
interaction while for muPECAM-1-D39
exon 14 (B) and muPECAM-1-686Y®F
(D) the majority of the aggregates con-
sisted only of transfected cells, indicative
of homophilic binding. The data is repre-
sentative of at least two experiments. All
the transfectants described above ex-
pressed PECAM-1 at comparable levels
by FACS® analysis (mean [log] fluores-
cence intensities of 100–120).Famiglietti et al. Exon 14 Regulates PECAM-1 Ligand Specificity 1429
Since the muPECAM-D39 exon 14 mutant showed a pat-
tern characteristic of homophilic aggregation, while the
muPECAM-DRKVDP aggregated in a heterophilic man-
ner, these data indicate that the presence of the VYSEI re-
gion was the critical region to confer heterophilic binding.
Mutation of a Single Amino Acid in Exon 14
(the Tyrosine at AA686) Can Convert Heterophilic
to Homophilic Binding
As mentioned above, the VYSEI sequence fits criteria for
a potential SH2 binding domain. To determine if this ty-
rosine was important in the ability of this sequence to reg-
ulate PECAM-1 function, an additional construct was
made in which the tyrosine at amino acid 686 was mutated
to a phenylalanine (muPECAM-1-686Y®F, Fig. 1 F).
After transfecting and isolating L cells expressing this con-
struct at comparable levels, multiple clones were tested in
mixed aggregation assays. As shown in Fig. 2 D, these cells
aggregated in a homophilic manner. This experiment indicates
that mutation of a single amino acid in exon 14 (the tyrosine
at AA686) can convert heterophilic to homophilic binding.
PECAM-1 Can Be Phosphorylated on Tyrosine after 
Treatment with Sodium Orthovanadate
The results described above indicate that the tyrosine in
exon 14 plays a role in the ligand specificity of PECAM-1.
It was therefore of interest to study the effects of en-
hanced tyrosine phosphorylation on PECAM-1 function.
PECAM-1 is known to be phosphorylated primarily on
serine and threonine residues (Newman et al., 1992; Zhender
et al., 1992). However, recent studies have identified con-
ditions where tyrosine phosphorylation has also been ob-
served (Modderman et al., 1994; Lu et al., 1996; Newman,
1997). To examine the status of tyrosine phosphorylation
in L cells transfected with full-length PECAM-1, cells were
immunoprecipitated with a polyclonal antibody against
huPECAM (Houston) and transferred to nitrocellulose
where they were then immunoblotted with either an mAb
to huPECAM-1 (mAb 1.3) or an mAb recognizing phos-
photyrosine. HuPECAM-1 was used in these studies since
an antibody capable of immunoblotting murine PECAM
was not available and we have observed no differences in
the behavior of muPECAM and huPECAM with regard
to the presence or absence of exon 14 (DeLisser et al., 1993;
Yan et al., 1995; Sun et al., 1996).
As shown in Fig. 3 (lane 1), under resting conditions, L
cells expressing huPECAM-1 show very low levels of ty-
rosine phosphorylation. Treatment of cells with the ty-
rosine phosphatase inhibitor, sodium orthovanadate, how-
ever, prevented dephosphorylation and resulted in very
high steady state levels of PECAM-1 tyrosine phosphory-
lation (Fig. 3, lane 2). As a control, treatment of L cells ex-
pressing a mutant form of huPECAM-1 lacking the exons
11–16 (PECAM-D11–16) showed no evidence of tyrosine
phosphorylation before (Fig. 3, lane 3) or after (Fig. 3,
lane  4) treatment with sodium orthovanadate.
Tyrosine Phosphorylation of PECAM Converts 
Heterophilic to Homophilic Binding
Having demonstrated that treatment of PECAM-express-
ing L cells with sodium orthovanadate led to high levels of
tyrosine phosphorylation, the functional result of this
change was analyzed by performing aggregation studies.
Sham-transfected L cells, which normally aggregate at
very low levels in the presence or absence of calcium were
not induced to aggregate by the addition of sodium vana-
date (Fig. 4 A). As described before, L cells expressing
full-length huPECAM aggregated in a calcium-dependent,
heterophilic fashion (Fig. 4 A). Exposure of these cells to
orthovanadate, however, changed the aggregation pattern
Figure 3. Immunoprecipitation and immunoblotting of PECAM-1
mutants with anti-PECAM and anti-phosphotyrosine antibodies.
L cells expressing full-length huPECAM-1 (lanes 1 and 2), huPE-
CAM-1 lacking exons 11–16 (PECAMD11–16, lanes 3 and 4), and
huPECAM-1 lacking exons 11–16 with the addition of exon 14
(PECAM-9,10,14, lanes 5 and 6) were immunoprecipitated with a
polyclonal antiserum directed against huPECAM-1, transferred
to nitrocellulose, and immunoblotted with a monoclonal anti-
body directed against either huPECAM-1 (upper panel) or phos-
photyrosine (lower panels). Cells were first exposed to control
media (Vanadate 2) or to media containing sodium orthovana-
date for 24 h (Vanadate 1). The upper panels show uniform ex-
pression of PECAM-1 under these conditions. Note that the mu-
tant forms of PECAM-1 have a slightly lower molecular weight.
Under control conditions, little or no phosphotyrosine was de-
tected in the full-length PECAM-1 (lane 1) or in either mutant
(lanes 3 and 5). Treatment of cells with the tyrosine phosphatase
inhibitor, sodium orthovanadate, however, induced very high lev-
els of PECAM-1 tyrosine phosphorylation (lane 2). In contrast, L
cells expressing PECAM-D11–16 did not exhibit tyrosine phos-
phorylation before (lane 3) or after (lane 4) treatment with so-
dium orthovanadate. However, orthovanadate treatment of cells
expressing PECAM-9,10,14 resulted in the appearance of a
strong band (lane 6) indicating that the tyrosine on exon 14 was
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to one that was more robust and calcium independent.
When mixed aggregation studies were performed, a pat-
tern consistent with homophilic aggregation was observed
(data not shown). Although our initial studies were per-
formed after exposure of cells to vanadate for 24 h, the ef-
fect of vanadate was much more rapid. Fig. 4 B shows a
time course experiment, where the full effects of orthovan-
adate were evident when the compound was added only
during the aggregation assay (z1 h of exposure).
Additional controls were performed to document the
specificity of this response. Cells expressing a mutant form
of huPECAM-1 lacking the entire cytoplasmic domain
(PECAM-DCD) have no ability to aggregate under nor-
mal conditions (DeLisser et al., 1994b). Addition of ortho-
vanadate did not induce aggregation (Fig 4 A). To further
document that the change in aggregation behavior was
PECAM dependent, the ability of an anti-PECAM poly-
clonal antibody that has previously been shown to inhibit
PECAM-mediated aggregation (Albelda et al., 1991) was
tested. As shown in Fig. 4 C, addition of this antibody to
cells expressing full-length huPECAM-1 in the presence of
othovanadate blocked both calcium-dependent and -inde-
pendent aggregation nearly completely.
Similar results were also observed using L cells express-
ing the murine form of PECAM-1. As shown in Fig. 5,
exposure of muPECAM-1–transfected L cells to ortho-
vanadate for a period as short as 1 h converted calcium-
dependent, heterophilic (Fig. 5, A and B) aggregation to
calcium-independent, homophilic (Fig. 5, A and C) aggrega-
tion.
Thus, in cells expressing either human or murine PE-
CAM-1, tyrosine phosphorylation of PECAM converts
heterophilic to homophilic binding.
Tyrosine Phosphorylation of Exon 14 of PECAM-1 
Converts Heterophilic to Homophilic Binding
The experiments described above establish that tyrosine
Figure 4. Aggregation of L cell transfec-
tants expressing huPECAM-1 before and
after sodium orthovanadate treatment.
(A) Standard aggregation studies were
performed with and without (1 mM) cal-
cium and with and without 24 h of pre-
treatment with sodium orthovanadate in
sham-transfected L cells, L cell transfec-
tants expressing full-length huPECAM-1,
and L cells expressing a mutant of PE-
CAM-1 lacking the cytoplasmic domain
(huPECAM-1DCD). Sham-transfected L
cells and L cells expressing huPECAM-
1DCD did not aggregate in the presence or
absence of calcium. No aggregation was
induced by exposure to vanadate. As ex-
pected, L cells expressing full-length hu-
PECAM-1 demonstrated calcium-depen-
dent aggregation under control conditions.
Exposure of these cells to orthovanadate,
however, changed the aggregation pat-
tern to one that was more robust and cal-
cium independent. (B) Time course. Stan-
dard aggregation studies were performed
with and without calcium (1 mM) in L cell
transfectants expressing full-length huPE-
CAM-1. The cells were exposed to media
containing sodium vanadate for various
lengths of time. Augmentation of aggrega-
tion and conversion to calcium-indepen-
dent aggregation occurred after as little as
1 h of exposure to vanadate. (C) Antibody
inhibition studies. Standard aggregation
studies were performed with and without
calcium (1 mM) in L cell transfectants ex-
pressing full-length huPECAM-1 in the
presence or absence of sodium orthovana-
date and a polyclonal anti–huPECAM an-
tibody. Exposure of cells to orthovanadate
changed the aggregation pattern to one that
was more robust and calcium indepen-
dent. Both calcium- and calcium-indepen-
dent aggregation was blocked to nearly baseline levels by the anti–PECAM-1 antibody. These data presented are from at least three ex-
periments done in duplicate or triplicate and of at least two independent clones. Bars represent mean values. Error bars depict the
standard error of the mean. All the transfectants described above expressed PECAM-1 at comparable levels by FACS® analysis (mean
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phosphorylation of the cytoplasmic domain can change
ligand specificity of mu- or huPECAM-1; however, they
do not specifically implicate exon 14 as there are 5 ty-
rosines that are potential phosphorylation sites within the
cytoplasmic domain (in exons 9, and 12–15). To determine
the functional importance of phosphorylation of this ty-
rosine, we needed to study a form of PECAM-1 that (a)
contained the tyrosine in exon 14, (b) aggregated in a het-
erophilic manner, and (c) did not include other regions of
the cytoplasmic domain that contained tyrosine residues
that could be phosphorylated after exposure to sodium
vanadate.
To determine if phosphorylation of exon 14 alone could
induce changes in ligand binding, we therefore used two
previously described huPECAM-transfected L cell lines
(Sun et al., 1996). huPECAM-1D11–16 contains the extra-
cellular and transmembrane domains of huPECAM-1,
plus a small portion of the cytoplasmic domain that con-
tains exons 9 and 10. This construct thus contains only the
tyrosine in exon 9. As described before, L cells transfected
the huPECAM-1D11–16 aggregate in a homophilic man-
ner. huPECAM-1(1)9,10,14 is identical to huPECAM-
1D11–16 except that the cytoplasmic domain also contains
all of exon 14 at its 39 end. In contrast to huPECAM-
1D11–16, L cells transfected with this construct aggregate
in a heterophilic manner (Sun et al., 1996); therefore, the
ability of vanadate treatment to convert this form of hu-
PECAM-1 to homophilic binding would strongly implicate
the tyrosine in exon 14 as being important.
L cells containing these two constructs were immuno-
precipitated with anti–PECAM-1 antibody and then im-
munoblotted with antibodies against PECAM-1 or phos-
photyrosine before and after treatment with vanadate. As
shown in Fig. 3, the huPECAM-1D11–16 expressing cells
showed no evidence of tyrosine phosphorylation either be-
fore or after orthovanadate (lanes 3 and 4), thus indicating
that the tyrosine in exon 9 is not phosphorylated under
these conditions. In contrast, the immunoblot of huPE-
CAM-1 (1)9,10,14 after orthovanadate treatment (com-
pare lane 5 with lane 6) shows a strong band, indicating
that the tyrosine on exon 14 is phosphorylated under these
conditions, although it is formally possible that the ty-
rosine on exon 9 was also phosphorylated (in the presence
of exon 14).
To determine the functional significance of this phos-
phorylation, L cells transfected with huPECAM-1(1)
9,10,14 were tested in a mixed aggregation assay with and
without orthovanadate. As shown in Fig. 6, addition of
orthovanadate converted binding from calcium-dependent
heterophilic aggregation to calcium-independent homophilic
aggregation.
Thus, phosphorylation of the tyrosine in exon 14 has the
ability to convert heterophilic to homophilic binding.
Discussion
Previous studies using L cell aggregation as a model for
PECAM-1–mediated adhesion have implicated a small re-
gion of the cytoplasmic domain, exon 14, as being central
in regulating the ligand binding specificity of both mu- and
huPECAM-1 (DeLisser et al., 1994b; Yan et al., 1995; Sun
et al., 1996). The purpose of this study was to isolate the
Figure 5. Aggregation of full-length muPECAM-1 L cell trans-
fectants with and without exposure to sodium othovanadate.
Standard and mixed aggregation studies were performed with
and without (1 mM) calcium and with and without 1 h of pre-
treatment with sodium orthovanadate in L cell transfectants of
full-length muPECAM-1. In standard aggregation studies, (A) L
cells expressing full-length huPECAM-1 demonstrated calcium-
dependent aggregation under control conditions. Identical to the
huPECAM-1 cells, exposure to orthovanadate, however, changed
the aggregation pattern to one that was more robust and calcium
independent. Bars represent mean values from at least three ex-
periments. Error bars depict the standard error of the mean. In
mixed aggregation assays (with 1 mM calcium), the transfectants
of muPECAM-1 without exposure to vanadate formed mixed ag-
gregates (heterophilic interaction) (B), while the cells expressing
muPECAM-1 after 1 h of exposure to sodium orthovanadate
formed primarily self-aggregates (homophilic interaction) (C).
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precise region of this exon responsible for this activity and,
by doing so, help elucidate the mechanism by which it reg-
ulated specificity. Since removal of all exon 14 converted
heterophilic to homophilic binding, a series of deletion
mutants were created in which smaller regions of exon 14
were removed. After transfection into L cells, they were
tested for their ability to mediate aggregation. The results
of these studies (Fig. 1) show that for heterophilic aggrega-
tion to occur, a conserved 5-amino acid region (VYSEI in
the murine sequence or VYSEV in the human sequence)
in the mid-portion of the exon must be present. Con-
versely, loss of this small region converted heterophilic to
homophilic binding. Because this region contains a ty-
rosine in the context of a potential SH2 binding region, a
final construct was generated in which the only mutation
was the conservative change of this tyrosine into a phen-
ylalanine. Unlike L cells expressing wild-type PECAM-1,
L cells expressing this Y®F mutant construct aggregated
in a homophilic manner, implicating this tyrosine as criti-
cally important in the regulation of ligand binding. A simi-
lar mutation in the same tyrosine of huPECAM (Y686)
has also recently been shown to affect migration rates in
PECAM-1–transfected 3T3 cells (Lu et al., 1996).
The role of this tyrosine was further explored in a series
of experiments examining the effects of enhanced phos-
phorylation of PECAM-1. This was accomplished by in-
hibiting tyrosine phosphatase activity by exposing cells to
sodium orthovanadate using a protocol recently described
by Lu et al. (1996). Similar to the findings of this group
and others (Newman et al., 1992; Zhender et al., 1992), we
found that at baseline, PECAM-1 showed only very low
levels of tyrosine phosphorylation using a sensitive immu-
noprecipitation/immunoblotting technique. Inhibition of
phosphatase activity by a short exposure to sodium ortho-
vanadate, however, resulted in high levels of cytoplasmic
tyrosine phosphorylation (Fig. 3). Interestingly, this en-
hanced phosphorylation of PECAM-1 led to a switch from
heterophilic to homophilic aggregation. Although ortho-
vanadate treatment of cells leads to global increases in ty-
rosine phosphorylation, specificity of this observation with
regard to PECAM-1 was confirmed by (a) lack of effect of
sodium orthovanadate in nontransfected L cells, (b) lack
of effect in L cells transfected with forms of PECAM-1
lacking the cytoplasmic domain, and (c) the ability of an
anti–PECAM-1 antibody to inhibit the phosphatase-induced
homophilic aggregation. Although there are four tyrosines
that can potentially undergo phosphorylation after treat-
ment with orthovanadate, phosphorylation of the tyrosine
on exon 14 was shown to be sufficient to induce conver-
sion of heterophilic to homophilic aggregation in experi-
ments using L cells expressing a construct containing ex-
ons 9, 10, and 14. Cells expressing this construct undergo
heterophilic aggregation under control conditions (Sun et
al., 1996). However, exposure of these cells to orthovana-
date induced both tyrosine phosphorylation (Fig. 3) and
conversion to homophilic aggregation (Fig. 6).
Our data thus indicate either loss of the tyrosine in exon
14 (by deletion or mutation) or phosphorylation of this ty-
rosine (by inhibition of phosphatase activity) results in a
change in ligand specificity from heterophilic to ho-
mophilic binding. At first glance, these data appear diffi-
cult to reconcile; however, the unifying feature in both
Figure 6. Aggregation of huPECAM-1–9,10,14 L cell transfec-
tants with and without exposure to sodium orthovanadate. Stan-
dard and mixed aggregation studies were performed with and
without (1 mM) calcium and with and without 24 h of pretreat-
ment with sodium orthovanadate in L cell transfectants of huPE-
CAM-1 lacking exons 11–16 with the addition of exon 14 (huPE-
CAM-1–9,10,14). In standard aggregation studies (A), L cells
expressing huPECAM-1–9,10,14 demonstrated calcium-depen-
dent aggregation under control conditions. Exposure to ortho-
vanadate, however, changed the aggregation pattern to one that
was more robust and calcium-independent. Bars represent mean
values from at least three experiments. Error bars depict the stan-
dard error of the mean. In mixed aggregation assays, the transfec-
tants of huPECAM-1–9,10,14 without exposure to vanadate
formed mixed aggregates (heterophilic interaction) (B), while the
cells expressing huPECAM-1–9,10,14 after 1 h of exposure to so-
dium orthovanadate formed primarily self-aggregates (homophilic
interaction) (C). These data are representative of at least three
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conditions is a loss of the normal nonphosphorylated ty-
rosine residue, suggesting that this amino acid is critical for
a potential protein–protein interaction. Although a great
deal of attention has been paid to understanding the
mechanisms of the binding of cytoplasmic proteins (i.e.,
SH2 and SH3 domain-containing proteins) to phosphory-
lated tyrosine residues (i.e., Songyang et al., 1993), there is
at least one other example of protein interactions that de-
pend on the presence of nonphosphorylated molecules
and, in fact, are inhibited by tyrosine phosphorylation.
Galcheva-Gargova et al. (1996) have recently described a
zinc finger protein termed ZPR1 that binds only to the cy-
toplasmic tyrosine kinase domain of the epidermal growth
factor receptor (EGFR) when the receptor is in its nonac-
tivated, nonphosphorylated state. Treatment of cells with
ligand (EGF) induced tyrosine phosphorylation of the
EGFR and caused decreased binding of ZPR1. We specu-
late that a similar type of interaction may be occurring
with PECAM-1 and thus hypothesize (Fig. 7) that under
baseline conditions, when full-length PECAM-1 is in its
nonphosphorylated state, it interacts with a cytoplasmic
protein (a theoretical PECAM binding protein [PBP])
that binds to a region of the cytoplasmic domain at or near
the tyrosine in exon 14 (Fig. 7 A). This binding appears to
keep PECAM-1 in a form that favors heterophilic binding.
Potential mechanisms for this effect could be induction of
a conformation change that is transmitted to the extracel-
lular domain or, possibly, as shown in Fig. 7, maintenance
of PECAM-1 in a monomeric, nondimerized form, a confor-
mation that we believe favors heterophilic binding (Sun et
al., 1996). We postulate that either loss of the tyrosine in
exon 14 due to deletion/mutation (Fig. 7 B) or phosphory-
lation of this tyrosine (Fig. 7 C) inhibits the interaction of
PECAM-1 with this PBP that then allows either a confor-
mational change or favors the formation of homodimers
that promote homophilic binding (Fig. 7 D). It is also pos-
sible, as has been recently speculated by Newman
(1997), that PECAM-1–induced heterophilic aggregation
is mediated by a second molecule. In our schema, loss of a
PBP bound to the tyrosine in exon 14 that transmitted a
signal to this other L cell adhesion protein could also lead
to a loss of PECAM-1–induced heterophilic aggregation.
A search for such a PECAM-1 binding protein is currently
underway in our laboratory.
It is intriguing to note that a very similar tyrosine-con-
taining sequence (IYSEVKK) is also present in the cyto-
plasmic domain of biliary glycoprotein (BGP/CD66a), an
immunoglobulin superfamily molecule related to carcino-
embryonic antigen found on granulocytes and other cells
(Rojas et al., 1990; Afar et al., 1992). Biliary glycoprotein
can also be alternatively spliced, and vanadate treatment
leads to increased phosphorylation (Afar et al., 1992). In-
terestingly, phosphorylation of the analogous tyrosine-
containing region leads to binding of the protein tyrosine
phosphatase SHP-1 (Beauchemin et al., 1997). The func-
tional consequences of these events on the cell adhesion
properties of BGP, which can participate in homotypic
and heterotypic binding (Oikawa et al., 1992), have not
been described.
It is becoming clear that the tyrosine phosphorylation
status of PECAM-1 may be a critical factor in regulating
the function of the molecule. Although initial studies of
PECAM-1 found evidence of serine and threonine phos-
phorylation without tyrosine phosphorylation (Newman et
al., 1992; Zehnder et al., 1992), a number of recent studies
have begun to define conditions where tyrosine phosphor-
ylation has been detected. Lu et al. (1996) found that
PECAM-1 was tyrosine phosphorylated in cells after
trypsinization and suggested that b1 integrin engagement
might induce PECAM-1 dephosphorylation. More recently,
this group has found that the tyrosine phosphorylation sta-
tus of Tyr686 changes during vasculogenesis in the murine
conceptus (Pinter et al., 1997) and that phosphorylation of
this tyrosine could be induced by cSrc (Lu et al., 1997). Ty-
rosine phosphorylation of PECAM-1 has also been ob-
served in endothelial cells after mechanical stimulation
(Osawa et al., 1997) and after aggregation of the high af-
finity IgE receptor in a basophilic cell line (Sagawa et al.,
1997). Tyrosine phosphorylation of platelet PECAM-1 has
also been observed (Modderman et al., 1994; Newman,
1997).
In addition to our evidence that the phosphorylation
status of Y686 in PECAM-1 regulates ligand specificity, ty-
rosine phosphorylation is also likely to be important in
other functions of PECAM-1. Recent work by Newman’s
group (Jackson et al., 1997), suggests that phosphorylation
of the tyrosines in exons 13 and 14 provide a docking site
for the protein tyrosine phosphatase, SHP-2. SHP-2 may
then function as an active phosphatase or serve as a dock-
ing protein. Although PECAM-1 is not tyrosine phos-
phorylated under the conditions of our aggregation assay
(data not shown) and thus not expected to interact with
Figure 7. Proposed mechanism for the role of exon 14 in PE-
CAM-1–dependent adhesion. (A) Under baseline conditions,
when full-length PECAM-1 is in its nonphosphorylated state, it
interacts with a cytoplasmic protein (a PBP, PECAM binding
protein) that binds to a region of the cytoplasmic domain at or
near the tyrosine in exon 14. This interaction appears to keep PE-
CAM-1 in a form that favors heterophilic binding. Potential
mechanisms for this effect could be induction of a conformation
change that is transmitted to the extracellular domain, or possibly
maintenance of PECAM-1 in a monomeric, nondimerized form,
a conformation that we believe favors heterophilic binding. Ei-
ther loss of the tyrosine in exon 14 due to deletion/mutation (B)
or phosphorylation of this tyrosine (C) inhibits the interaction of
PECAM-1 with this PBP that then allows either a conformational
change or favors the formation of homodimers that promote ho-
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SHP-2, we did specifically look for evidence of SHP-2/PE-
CAM-1 association by coimmunoprecipitation/immuno-
blot analysis before, during, and after aggregation. Despite
seeing SHP-2 association with PECAM-1 after vanadate
treatment, we found no evidence of PECAM-1–tyrosine
phosphorylation during aggregation and, as expected, no
association of SHP-2 with PECAM-1 during the aggrega-
tion process (data not shown). Thus, while the interaction
of SHP-2 and PECAM-1 likely plays a role in “outside-in”
signaling, we found no evidence to suggest that this associ-
ation is directly involved in determining ligand specificity.
In summary, we have identified a unique mechanism for
control of ligand specificity in an important cell adhesion
molecule. By processes such as alternative splicing or reg-
ulation of the balance between tyrosine phosphorylation/
dephosphorylation, vascular cells could determine whether
PECAM-1 functions as a heterophilic or homophilic adhe-
sion molecule. Both of these mechanisms appear to be op-
erative during cardiovascular development (Baldwin et al.,
1994; Pinter et al., 1997). Defining other conditions under
which these changes occur will be important in under-
standing the biology of PECAM-1 in transmigration, an-
giogenesis, inflammation, and other processes in which
this molecule might play an important role.
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